Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity
This agreement is in addition to the $92 million filling line expansion announced in November 2021
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Subscribe To Our Newsletter & Stay Updated